Michael Glantz
Overview
Explore the profile of Michael Glantz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tuohy K, Dowd R, Ali A, Badani A, Sichinga K, Zacharia B, et al.
Neurosurgery
. 2025 Jan;
PMID: 39775083
Background And Objectives: Administration of intraventricular chemotherapy through Ommaya reservoir is indicated for certain forms of leptomeningeal disease. However, ventricular reservoirs carry a substantial risk of infection. The conventional approach...
2.
Pearlman A, Wang Y, Kalluri A, Parker M, Cohen J, Dudley J, et al.
medRxiv
. 2024 Dec;
PMID: 39677487
Statement Of Significance: There is a paucity of technologies beyond surgical biopsy that can accurately diagnose central nervous system neoplasms. We developed a novel, sensitive and highly specific assay that...
3.
Ozair A, Wilding H, Bhanja D, Mikolajewicz N, Glantz M, Grossman S, et al.
Nat Rev Clin Oncol
. 2024 Dec;
22(2):134-154.
PMID: 39653782
Leptomeningeal metastatic disease (LMD), encompassing entities of 'meningeal carcinomatosis', neoplastic meningitis' and 'leukaemic/lymphomatous meningitis', arises secondary to the metastatic dissemination of cancer cells from extracranial and certain intracranial malignancies into...
4.
Wilcox J, Chukwueke U, Ahn M, Aizer A, Bale T, Brandsma D, et al.
Neuro Oncol
. 2024 Jun;
26(10):1781-1804.
PMID: 38902944
Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer,...
5.
Mikolajewicz N, Yee P, Bhanja D, Trifoi M, Miller A, Metellus P, et al.
J Clin Oncol
. 2024 Apr;
42(16):1961-1974.
PMID: 38608213
Effective diagnosis, prognostication, and management of CNS malignancies traditionally involves invasive brain biopsies that pose significant risk to the patient. Sampling and molecular profiling of cerebrospinal fluid (CSF) is a...
6.
Cioffi G, Waite K, Dmukauskas M, Glantz M, Aulakh S, Nicolaides T, et al.
Neurooncol Adv
. 2024 Mar;
6(1):vdae031.
PMID: 38476929
No abstract available.
7.
Douville C, Curtis S, Summers M, Azad T, Rincon-Torroella J, Wang Y, et al.
Cell Rep Med
. 2023 Aug;
4(8):101148.
PMID: 37552989
It is often challenging to distinguish cancerous from non-cancerous lesions in the brain using conventional diagnostic approaches. We introduce an analytic technique called Real-CSF (repetitive element aneuploidy sequencing in CSF)...
8.
Darabi S, Xiu J, Samec T, Kesari S, Carrillo J, Aulakh S, et al.
Med Oncol
. 2023 Jun;
40(7):197.
PMID: 37291277
Gliomas are the most prevalent neurological cancer in the USA and care modalities are not able to effectively combat these aggressive malignancies. Identifying new, more effective treatments require a deep...
9.
Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, et al.
Eur J Cancer
. 2023 Jun;
189:112913.
PMID: 37277265
Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with...
10.
David K, Sundaram S, Kim S, Vaca R, Lin Y, Singer S, et al.
Am J Hematol
. 2023 Mar;
98(6):900-912.
PMID: 36965007
There is a paucity of large-scale data delineating outcomes and prognostication of older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL patients ages ≥60 ...